| Entries |
| Document | Title | Date |
|---|
| 20080280344 | Subtilase Variants Having Altered Immunogenictiy - The present invention relates to subtilase subtilases with an altered immunogenicity, particularly subtilases with a reduced allergenicity. Furthermore, the invention relates to expression of said subtilase variants and subtilases and to their use, such as in detergents and oral care products. | 11-13-2008 |
| 20080280345 | Screening Method - The present invention relates to a method for screening for variant peptides using mass spectrometry (MS). The present invention also relates to a system and a kit for performing the method. | 11-13-2008 |
| 20090047723 | METHOD FOR PURIFICATION OF FACTOR VII - A method for purifying recombinant Factor VII (rFVII) or recombinant activated Factor VII (rFVIIa), comprising subjecting the rFVII or rFVIIa to liquid chromatography on a hydroxyapatite (HAP) column. | 02-19-2009 |
| 20090047724 | METHOD FOR THE ISOLATION OF NUCLEIC ACIDS FROM ANY STARTING MATERIAL - A composition suitable for the isolation of a nucleic acid from a material containing the nucleic acid contains at least one buffer with a chaotropic component; at least one proteolytic enzyme; at least one buffer with an non-chaotropic component; at least one alcoholic component; and a detergent. | 02-19-2009 |
| 20090053787 | Method for refolding enzymes - The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with a denaturant at high pH in the presence of a reducing agent, diluting the solubilized BACE polypeptide in an aqueous solution at a temperature of about 1° C. to 15° C., and incubating the diluted sample at a temperature of about 4° C. to 15° C. until the recombinant BACE polypeptide folds into an active enzyme. | 02-26-2009 |
| 20090087895 | EXPRESSION VECTORS FOR PRODUCING TAG-CLEAVABLE FUSION PROTEINS IN MULTIPLE EXPRESSION SYSTEMS - This invention features a kit containing multiple expression vectors for producing tag-cleavable fusion proteins in various expression systems, or for producing fusion proteins in | 04-02-2009 |
| 20090148924 | PROTEASES AND VARIANTS THEREOF - The present invention relates to isolated proteases of the RP-II type and variants of RP-II proteases exhibiting improved properties in comparison to the parent RP-II protease, DNA constructs and vectors coding for the expression of said proteases and variants, host cells capable of expressing the proteases and variants from the DNA constructs, as well as a method of producing them by cultivating said host cells. The proteases may advantageously be used as constituents in detergent compositions and additives, optionally in combination with other enzymes such as proteases, lipases, cellulases, amylases, peroxidases or oxidases. | 06-11-2009 |
| 20090170182 | LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention refers to pharmaceutical compositions and cosmetic compositions comprising a prophylactic or therapeutically effective quantity of at least one polypeptide substantially identical to Lopap (a lipocalin-related protein with prothrombin activating protease activity). The invention refers to the use of these compositions as modulators of cell death and anti-aging agents. | 07-02-2009 |
| 20090203110 | COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV - The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production. | 08-13-2009 |
| 20090263882 | Thermostable Neutral Metalloproteases - The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved storage stability. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications. In some particularly preferred embodiments, the present invention provides methods and compositions comprising neutral metalloprotease(s) obtained from | 10-22-2009 |
| 20090280554 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 11-12-2009 |
| 20090305383 | Early Detection of Pathogens in Blood - The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na | 12-10-2009 |
| 20090317890 | FIBRIONOLYTIC METALLOPROTEASE AND COMPOSITION COMPRISING THE SAME - The present invention relates to a novel protease, a polynucleotide encoding the protease, and a fibrinolytic agent comprising the same. The protease is obtained from a new gene source by using metagenomic library technology, and can replace the conventional fibrinolytic agent. | 12-24-2009 |
| 20100047894 | Use of Matrix Metalloproteinases, Mutated and Not Mutated, for the Preparation of Pharmaceutical Compositions, and Mutated Metalloproteinases with Increased Stability - The use of matrix metalloproteinases, mutated and not mutated, for the preparation of pharmaceutical compositions useful in the treatment of pathologies associated with an accumulation of matrix bio-polymers and/or an excess of TIMPs (Tissue Inhihitors MetalloProteinases) is described; mutated matrix metalloproteinases, in which at least an aminoacid residue in a definite position in the protein, has been mutated into a hydrophilic and/or charged aminoacidic residue, obtaining an increased stability toward autoproteolysis are also described. | 02-25-2010 |
| 20100062512 | PURIFICATION OF FACTOR XI - The invention provides methods for purifying blood coagulation Factor XI from biological fluids, the methods comprising a step of hydrophobic charge induction chromatography (HCIC). | 03-11-2010 |
| 20100105121 | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon - Provided herein is are polypeptides that include the protease domain of a type II transmembrane serine protease (MTSP) as a single chain. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP are provided. Also provided are MTSPs designated MTSP3 and MTSP4 and a form of an MTSP designated MTSP6. | 04-29-2010 |
| 20100112665 | Crystallization and Structure Determination of Glycosylated Human Beta Secretase, an Enzyme Implicated in Alzheimer's Disease - An inhibitor bound form of human beta secretase, also known as memapsin 2 and BACE, particularly in a glycosylated form as expressed in Chinese hamster ovary (CHO), HEK293 cells, or in insect cells as part of a Baculovirus expression system has been crystallized, and the three dimensional x-ray crystal structure has been solved to 3.2 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of human beta secretase activity. | 05-06-2010 |
| 20100120120 | HAEMOCOAGULASE - The present invention provides a venene haemocoagulase gene and its expression for the functional protein. The haemocoagulase gene of the present invention has a nucleotide sequence shown by the sequence list SEQ ID NO: 1 or the mutated nucleotide sequence formed by replacement, depletion, or addition of one or more nucleotide based on the said nucleotide sequence with an equivalent function. The said haemocoagulase has amino acid sequence shown by SEQ ID NO: 2. Haemocoagulase of the present invention has an obvious hemostatic effect, a broad effective dose range, safe and reliable application, which creates good conditions for the development of genetic engineering products of recombinant haemocoagulase in the future. | 05-13-2010 |
| 20100203616 | REFOLDED RECOMBINANT ALPHA SECRETASE CRYSTALS AND METHODS FOR PREPARING AND USING THE SAME - The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of β-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization. | 08-12-2010 |
| 20100304465 | Recombinantly Modified Plasmin - Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme. | 12-02-2010 |
| 20100323427 | INSULIN DEGRADING ENZYME CRYSTALS - The present invention provides apo crystals and co-crystals of insulin-degrading enzyme (IDE) and their uses in drug development. | 12-23-2010 |
| 20110008869 | ENGINEERED PROTEASES FOR AFFINITY PURIFICATION AND PROCESSING OF FUSION PROTEINS - The present invention is directed to the identification of a protease prodomain that is capable of binding a corresponding protease with high affinity. The protease prodomain of the present invention is fused to a second protein to form a protease prodomain fusion protein. The presence of a protease prodomain protein in a fusion protein allows for easy and selective purification of the second protein by incubation with the corresponding protease. | 01-13-2011 |
| 20110076742 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS - The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 03-31-2011 |
| 20110086412 | Multiply-Substituted Protease Variants - Novel enzyme variants including protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Such variant proteases have properties which are different from those of the precursor protease, such as altered wash performance. The substituted amino acid residue correspond to positions 27, 45, 170, 181, 251 and 271 of | 04-14-2011 |
| 20110086413 | Cell Culture Medium For ADAMTS Protein Expression - The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein. | 04-14-2011 |
| 20110086414 | Prion Disinfection - The invention relates to a methods and compositions for treating a surface, suspension or solution contaminated with a PrP | 04-14-2011 |
| 20110097782 | METHOD, AGENT, AND KIT FOR ISOLATING NUCLEIC ACIDS - A method for isolating nucleic acids is provided. The method includes providing a biological sample containing at least one nucleic acid, and mixing the biological sample with an isolating agent under a suitable condition to isolate the nucleic acids from the biological sample in single step, wherein the isolating agent contains 1-40 wt % of PEG and/or more than 30 wt % of low molecular weight alcohol, a salt, and a detergent. Isolated nucleic acids are bound to a solid support by changes in the solubility of nucleic acids. Additionally, the present invention further provides an isolating agent and kit for isolating nucleic acids. | 04-28-2011 |
| 20110151541 | Method for Producing Recombinant Stem Bromelain - The present invention relates to a method for producing recombinant stem bromelain. Total RNA is isolated from pineapple plant ( | 06-23-2011 |
| 20120003717 | STREPTOMYCES STRAIN THAT DECOMPOSES PROTEINS RECALCITRANT TO PROTEOLYSIS - The invention provides novel biologically pure cultures of microorganisms high in protease activity and capable of decomposing proteins recalcitrant to proteolysis as contained in garbage, waste water, organic waste liquids, industrial wastes and the like, a protease produced by such microorganisms and capable of decomposing proteins recalcitrant to proteolysis, and a method of utilizing the same. The novel culture is of a soil-derived microorganism belonging to | 01-05-2012 |
| 20120040436 | TYPE MILK-CLOTTING PROTEASE DERIVED FROM A MICROORGANISM - The present invention provides an improved type protease which comprises an amino acid sequence that is at least 75% identical to SEQ ID NO:3, said improved type protease has at least one mutation selected from the group consisting of: (A) replacement of glutamine corresponding to glutamine at position 265 in SEQ ID NO: 3 with an acidic amino acid; and (B) replacement of glutamine at position 266 in SEQ ID NO: 3 with an acidic amino acid, and wherein said improved type protease has milk-clotting activity. | 02-16-2012 |
| 20120058537 | CHIMERIC TRUNCATED AND MUTANT VARIANT OF TISSUE PLASMINOGEN ACTIVATOR (T-PA) RESISTANT TO PLASMINOGEN ACTIVATOR INHIBITOR-1 - The various embodiments herein provide a chimeric truncated and mutant variant of a tissue plasminogen activator (t-pa) and a method for preparing the same. According to an embodiment herein, the mutant variant comprises a signal sequence domain, followed by a chimeric tetrapeptide, followed by a tripeptide, followed by a kringle 2 domain, followed by a serine protease domain and a substituted amino acids at position 128-131. The substituted amino acids are AAAA (SEQ ID NO: 3) amino acids. The chimeric tetrapeptide is Gly-His-Arg-Pro (SEQ ID NO: 1). The chimeric tetrapeptide is at a position of 36 to 39 amino acid of the mutant variant. The tripeptide is Ser-Tyr-Glu. According to an embodiment herein, a chimeric truncated and mutant variant of a tissue plasminogen activator comprises a native t-pa deleted with Finger domain, a Growth Factor domain and a Kringle 1 domain, a chimeric tetrapeptide and a substituted amino acids at a position of 128-131. | 03-08-2012 |
| 20120115204 | VIRUS FILTRATION OF LIQUID FACTOR VII COMPOSITIONS - The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide). | 05-10-2012 |
| 20120149088 | ALKYLENE GLYCOLS AND POLYMERS AND COPOLYMERS THEREOF FOR DIRECT ISOLATION OF NUCLEIC ACID FROM EMBEDDED SAMPLES - Methods of directly isolating nucleic acid from an embedded biological sample are provided. An emulsified digest is generated in the presence of a thermostable protease, and an additive selected from an alkylene glycol, a poly(alkylene glycol), or a block copolymer having an average M | 06-14-2012 |
| 20120252096 | MUTANT PROTEINASE WITH REDUCED SELF-CLEAVAGE ACTIVITY AND METHOD OF PURIFICATION - The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins. | 10-04-2012 |
| 20120264190 | Decellularized and Delipidized Extracellular Matrix and Methods of Use - Compositions comprising decellularized and delipidized extracellular matrix derived from adipose or loose connective tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, or damaged adipose or loose connective tissues or organs in a subject, preferably a human, and/or for tissue engineering, filing soft tissue defects, and cosmetic and reconstructive surgery, using a decellularized and delipidized adipose or loose connective tissue extracellular matrix of the invention are provided. Methods of preparing tissue culture surfaces and culturing cells with adsorbed decellularized and delipidized adipose or loose connective tissue extracellular matrix are also provided. | 10-18-2012 |
| 20120295328 | METHOD FOR ISOLATING SMALL RNA - A method for isolating small RNA from a sample is provided, the method comprising binding the RNA to silica particles by contacting the sample with a) at least one alcohol, b) at least one chaotropic salt comprising a chaotropic anion selected from the group consisting of trichloroacetate, perchlorate and trifluoroacetate and c) silica particles and separating the bound RNA from the rest of the sample. The present invention also provides compositions and kits to efficiently isolate small RNA molecules from samples, in particular biological samples such as blood, blood products tissue and body fluids. | 11-22-2012 |
| 20120295329 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES SHOW IMPROVED CATALYTIC ACTIVITY AND CHIRAL SELECTIVITY - This invention provides novel chemically modified mutant serine hydrolases that catalyze a transamidation and/or a transpeptidation and/or a transesterification reaction. The modified serine hydrolases have one or more amino acid residues in a subsite replaced with a cysteine, wherein the cysteine is modified by replacing the thiol hydrogen in the cysteine with a substituent group providing a thiol side chain comprising a moiety selected from the group consisting of a polar aromatic substituent, an alkyl amino group with a positive charge, and a glycoside. In particularly preferred embodiments, the substitutents include an oxazolidinone, a C | 11-22-2012 |
| 20120301945 | PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 11-29-2012 |
| 20120301946 | THERMOLYSIN FOR EASY-CLEANING OF INSECT BODY STAINS - A substrate or coating is provided that includes a protease with enzymatic activity toward a component of a biological stain. Also provided is a process for facilitating the removal of a biological stain is provided wherein an inventive substrate or coating including a protease is capable of enzymatically degrading of one or more components of the biological stain to facilitate biological stain removal from the substrate or said coating. | 11-29-2012 |
| 20130065295 | Compositions and Methods Relating to Proteins Requiring Gamma-Carboxylation - The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a γ-glutamyl carboxylase and associated control sequences. The invention further relates to a method of producing a protein requiring gamma-carboxylation in high yields. | 03-14-2013 |
| 20130115682 | FUSION PROTEINS - The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell. | 05-09-2013 |
| 20130130354 | Novel genes and uses thereof, expression profile of colon, gastric and pancreatic cancer - This invention provides information on differentially expressed genes in malignant tissue of gastric, colon and pancreatic adenocarcinomas as compared to their corresponding adjacent non-malignant tissues. These genes or their products can be used as targets in developing new strategies for the treatment and diagnosis of these gastrointestinal cancers. | 05-23-2013 |
| 20130164820 | PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 06-27-2013 |
| 20130196413 | Engineered plant cysteine proteases and their uses - The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing. | 08-01-2013 |
| 20130217094 | ENZYME SOLUTION FOR SEPARATING CELL, METHOD FOR SEPARATING CELL AND METHOD FOR SEPARATING PANCREATIC ISLET - An enzyme solution for separating cell(s) which can lessen damage in separating a single cell or a mass of cells from a tissue or an organ, a method for separating cell(s) using the enzyme solution, and a method for separating pancreatic islet(s) using the enzyme solution. The enzyme solution for separating cell(s) is an enzyme solution containing a chloride ion channel inhibitor or having a chloride ion concentration of 10 mM or lower. By an enzymatic treatment using the enzyme solution for separating cell(s), a single cell or a mass of cells can be separated from a tissue or an organ. To separate pancreatic islet(s) from the pancreas, the enzyme is injected through the pancreatic duct to digest the pancreas. | 08-22-2013 |
| 20130224834 | ANTI-ANDROGENIC AGENT, SEBUM SECRETION BLOCKER, HAIR GROWTH STIMULANT, AND FOOD OR BEVERAGE - Provision of an anti-androgenic agent which has a strong anti-androgenic action, is free of side effects and very safe, and a sebum secretion blocker and a hair growth stimulant containing the anti-androgenic agent as an active ingredient. Provided are the anti-androgenic agent comprising lactoferrin, the sebum secretion blocker containing the anti-androgenic agent as an active ingredient, the hair growth stimulant containing the anti-androgenic agent as an active ingredient, and a food or drink product comprising the anti-androgenic agent containing lactoferrin as an active ingredient. | 08-29-2013 |
| 20130230901 | PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR - Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide. | 09-05-2013 |
| 20130267010 | Immuno-Based Retargeted Endopeptidase Activity Assays - The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed. | 10-10-2013 |
| 20130280787 | EXTRACTION OF NUCLEIC ACIDS FROM WAX-EMBEDDED SAMPLES - The present invention relates to a method for extracting nucleic acids from a wax-embedded sample, the use of particular solvents for removing wax from a wax-embedded sample in a method for extracting, isolating and/or purifying nucleic acids from a crosslinked wax-embedded sample as well as to a kit for extracting, isolating and/or purifying nucleic acids from a wax-embedded sample. | 10-24-2013 |
| 20130295646 | METHOD FOR EXTRACTING A PROTEIN FROM MILK - The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein. | 11-07-2013 |
| 20130309753 | RECOMBINANT AUTO-ACTIVATING PROTEASE PRECURSORS - A recombinant serine protease precursor that auto-activates in an aqueous buffer to form a mature active enzyme is disclosed. A contemplated precursor contains | 11-21-2013 |
| 20140030791 | Mutant MT-SP1 proteases with altered substrate specificity or activity - MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis. | 01-30-2014 |
| 20140080200 | METHODS OF PURIFYING POLYPEPTIDES - The present invention relates to improved processes for purifying polypeptides of interest by increasing the amount of a polypeptide of interest bound to an ion-exchange matrix relative to the amount of one or more impurities bound to the ion-exchange matrix. This effect is achieved by adding a chemical compound in the process which by also binding to the ion-exchange matrix due to a change that is opposite to the change of the ion-exchange matrix, reduces the binding of impurities more than the binding of the polypeptide of interest. | 03-20-2014 |
| 20140127782 | Subtilases - The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent. | 05-08-2014 |
| 20140287481 | Savinase Variants Having an Improved Wash Performance on Egg Stains - Subtilase variants having an improved wash performance on egg stains. These subtilases are useful exhibiting excellent or improved wash performance on egg stains when used in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. | 09-25-2014 |
| 20140302589 | METHODS AND SYSTEMS FOR PROTEIN REFOLDING - The invention provides methods and systems for production of recombinant protein, and particularly, for production of recombinant protein from inclusion bodies. For example, in one aspect, the method comprises providing a protein preparation comprising inclusion bodies, preparing an inclusion body dispersion, and exposing the protein preparation to high pressure in a pressure vessel, to disaggregate and refold the inclusion body protein. | 10-09-2014 |
| 20140322797 | Method for Removing Endotoxin from Proteins - Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing. | 10-30-2014 |
| 20140356929 | Expression Vector for an Improved Protein Secretion - The aim of the invention is to improve the secretion of a protein from a host cell in order to increase the product yield of protein in a fermentation process. This is achieved by an expression vector comprising a) a promoter sequence and b) a nucleic acid sequence that codes for a protein. The protein comprises a signal peptide and an additional amino acid sequence, and the signal peptide comprises an amino acid sequence that is at least 80% identical to the amino acid sequence specified in SEQ ID NO 2, at least 80% identical to the amino acid sequence specified in SEQ ID NO 4, at least 80% identical to the amino acid sequence specified in SEQ ID NO 6, or the signal peptide comprises an amino acid sequence that is structurally homologous to at least one of said sequences. | 12-04-2014 |
| 20140370570 | Use of a cysteine protease of Plasmodium vivax - A use of vivapain-4 (VX-4), which is a cysteine protease of | 12-18-2014 |
| 20150037872 | Protein Variants Having Modified Immunogenicty - The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 Å from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant. | 02-05-2015 |
| 20150376592 | PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR - Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide. | 12-31-2015 |
| 20160083711 | ASPARTIC PROTEASES - The invention relates to aspartic proteases, and particularly to aspartic proteases for plants. Disclosed are modified plant aspartic proteases, and methods for their manufacture, and uses thereof. Particularly contemplated are the uses of aspartic proteases in clotting milk. | 03-24-2016 |
| 20160159856 | AFFINITY TAGS AND PROCESSES FOR PURIFYING AND IMMOBILIZING PROTEINS USING SAME - The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag. | 06-09-2016 |
| 20160160159 | DETERGENT COMPOSITION COMPRISING PROTEASE VARIANTS - The present invention relates to detergent compositions comprising protease variants and methods for obtaining such detergent compositions. The present invention also relates to the use of such detergent compositions, especially in laundry or in hard surface cleaning applications. | 06-09-2016 |
| 20160177235 | DETERGENT COMPOSITION | 06-23-2016 |
| 20160177236 | DETERGENT COMPOSITION | 06-23-2016 |
| 20170233708 | EVOLUTION OF PROTEASES | 08-17-2017 |
| 20180023067 | Method For Producing A Recombinant Protein Of Interest | 01-25-2018 |
